Skip to main content
. Author manuscript; available in PMC: 2010 Nov 9.
Published in final edited form as: Lancet. 1995 Nov 18;346(8986):1346–1350. doi: 10.1016/s0140-6736(95)92349-7

Table.

Reasons given in published report of American multicentre study20 for withdrawal (censoring) for secondary end-point analysis*


Tacrolimus
Cyclosporin
Randomised
263
266
Total censored
83 (31·6%)
102 (38·3%)
Reasons for censoring
Death 14 (5·3%) 16 (6·0%)
2nd transplantation for technical problem 17 (6·5%) 21 (7·9%)
Adverse event 37 (14·1%) 13 (4·9%)
Lack of efficacy 6 (2·3%) 32 (12·0%)
Administrative 9 (3·4%) 20 (7·5%)
*

Data from table 3.